Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of plant cell expressed recombinant human glucocerebrosidase (prGCD) in Gaucher disease
2007-000498-42Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Jan 2008
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of taliglucerase alfa in Gaucher disease (GD) (2 arms), sponsored by Protalix BioTherapeutics. Primary endpoint: Change in spleen volume at 9 months. Started Jan 2008; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on 2007-000498-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000498-42.